Abstract
"Omics" and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas.
Highlights
While clinical results indicate the benefit of HER2-targeted treatment, the fact remains that this therapy administered according to current FDA/EMEA-approved protocols can only cure about 50% of patients with HER2-positive breast carcinoma [1]
2–4% present activating mutations within the kinase domain of ERBB2 analogous to those detected in EGFR and never coexisting with EGFR, KRAS, or ALK alterations [3,4,5]
Heterogeneity of HER2 amplification must be considered in clinical therapeutic decisions, despite pilot results suggesting that a similar trastuzumab benefit for patients with HER2 amplification, either diffuse or focal [9]
Summary
While clinical results indicate the benefit of HER2-targeted treatment, the fact remains that this therapy administered according to current FDA/EMEA-approved protocols can only cure about 50% of patients with HER2-positive breast carcinoma [1]. Molecular alterations of HER2 and its presence on the tumor cell membrane endow this oncoprotein with relevant immunological properties, making it an ideal target antigen for long-term cancer immunoprevention.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
